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Background. BRIP1 interacts with BRCA1 and functions in regulating DNA double strand break repair pathways. Germline
BRIP1 mutations are associated with breast cancer and Fanconi anemia. Thus, common variants in the BRIP1 are candidates for
breast and ovarian cancer susceptibility. Methods. We used a SNP tagging approach to evaluate the association between
common variants (minor allele frequency$0.05) in BRIP1 and the risks of breast cancer and invasive ovarian cancer. 12 tagging
SNPs (tSNPs) in the gene were identified and genotyped in up to 2,270 breast cancer cases and 2,280 controls from the UK and
up to 1,513 invasive ovarian cancer cases and 2,515 controls from the UK, Denmark and USA. Genotype frequencies in cases
and controls were compared using logistic regression. Results. Two tSNPs showed a marginal significant association with
ovarian cancer: Carriers of the minor allele of rs2191249 were at reduced risk compared with the common homozygotes (Odds
Ratio (OR) = 0.90 (95% CI, 0.82–1.0), P-trend= 0.045) and the minor allele of rs4988344 was associated with increased risk
(OR=1.15 (95%CI, 1.02–1.30), P-trend= 0.02). When the analyses were restricted to serous ovarian cancers, these effects
became slightly stronger. These results were not significant at the 5% level after adjusting for multiple testing. None of the
tSNPs was associated with breast cancer. Conclusions. It is unlikely that common variants in BRIP1 contribute significantly to
breast cancer susceptibility. The possible association of rs2191249 and rs4988344 with ovarian cancer risks warrant
confirmation in independent case-control studies.
Citation: Song H, Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, et al (2007) Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and
Susceptibility to Breast and Ovarian Cancer. PLoS ONE 2(3): e268. doi:10.1371/journal.pone.0000268
INTRODUCTION
Breast and ovarian cancer are among the most frequent cancers in
women in Western countries [1,2]. Combined, there were
approximately 49,000 cases of breast and ovarian cancer reported
in the United Kingdom in 2002 and more than 17,000 deaths
from these cancers in 2003. The main breast/ovarian cancer
predisposition genes so far identified are BRCA1 and BRCA2. They
are estimated to account for ,40% of the excess familial risk of
ovarian cancer and ,25% of the excess familial breast cancer risk
[3,4]. Thus, other breast/ovarian cancer susceptibility genes are
likely to exist. Linkage studies in non-BRCA1/2 breast cancer
families and segregation analysis in ovarian cancer families suggest
that a large fraction of the residual familial risks is due to multiple
alleles of moderate to low penetrance rather than additional high
penetrance susceptibility genes [5,6].
It is widely accepted that tumour formation is a multistep
process accompanied by an accumulation of multiple genetic
alterations. Tumour development is associated with a breakdown
in the mechanisms that control cell division and the maintenance
of genome integrity (e.g. DNA repair). Thus, genes involved in
these pathways represent good candidates for genetic susceptibil-
ity. BRIP1 (BRCA1-interacting protein 1), also called BACH1
(BRCA1-associated C-terminal helicase-1) and FANCJ (Fanconi
anemia complementation group J), belongs to the DEAH helicase
family [7,8]. It works as both a DNA-dependent ATPase and a
5-prime-to-3 prime DNA helicase, and is essential for DNA repair
and genomic stability [9]. It is universally expressed and
co-localised with BRCA1 in nuclear foci [7]. The complex formed
by BRIP1 and the BRCT repeats of BRCA1 is important for the
role of BRCA1 in its DNA double strand break repair and tumour
suppressor functions [7]. This specific interaction between BRCA1
and phosphorylated BRIP1 is regulated by the cell cycle and is
essential for DNA damage-induced checkpoint control during G2
to M phase transition [10]. Germline mutations in BRIP1 are
associated with Fanconi anemia, which is a chromosome instability
disorder characterized by developmental abnormalities, bone
marrow failure and predisposition to cancer [8,11]. Very recently,
a rare ptotein truncating variant in BRIP1 has been identified as
low-penetrance breast cancer susceptibility alleles [12].
The BRIP1 gene spans 180 kb, comprises 20 exons and encodes
a protein of 1,249 amino acids [7]. It is located on chromosome
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17q22, just distal to the BRCA1 gene located at 17q21 [13],
a region that is frequently somatically altered in both breast and
ovarian cancer [14–15].
Taken together, these data suggest that BRIP1 is a good
candidate for moderate/low penetrance genetic susceptibility to
breast and ovarian cancer. Several studies have already attempted
to evaluate the association of individual BRIP1 variants with breast
cancer risk either by mutation analysis or genotyping a few SNPs
within the gene [16–21], but only one included more than 1000
cases and none comprehensively evaluated all common variation
in the gene. The aim of this study was to evaluate whether
common variants in BRIP1 are associated with breast and ovarian
cancer risks using a SNP tagging approach within an association
study design.
MATERIALS AND METHODS
Breast cancer study subjects
Cases were drawn from SEARCH (breast cancer), an ongoing
population based study, with cases ascertained through the East
Anglian Cancer Registry. All patients diagnosed with invasive
breast cancer below age 55 years since 1991 and still alive in 1996
(prevalent cases, median age 48 years), together with all those
diagnosed ,70 years between 1996 and the present (incident
cases, median age 54 years) were eligible to take part. Sixty seven
percent of eligible breast cancer patients returned a questionnaire
and 64% provided a blood sample for DNA analysis. Controls
were randomly selected from the Norfolk component of EPIC
(European Prospective Investigation of Cancer) and somewhat
older than cases (median age 63 years) though from a broadly
similar age range. The ethnic background of cases and controls
was established from the questionnaire- more than 98% of all
subjects were white. The study has been approved by the Eastern
Region Multicentre Research Ethics Committee, and all patients
gave written informed consent. In total, 4473 cases and 4560
controls were available for analysis.
The samples were split into two sets in order to save DNA and
reduce genotyping costs: the first set (n = 2270 cases and 2280
controls) was genotyped for all SNPs and the second set (n = 2203
cases and 2280 controls) were then tested for those SNPs that
showed marginally significant associations in set 1 (P-heterogeneity
or P-trend,0.1). This staged approach substantially reduces
genotyping costs without significantly affecting statistical power.
Cases were randomly selected for set 1 from the first 3,500
recruited, with set 2 comprising the remainder of these plus the
next 974 incident cases recruited. As the prevalent cases were
recruited first, the proportion of prevalent cases was somewhat
higher in set 1 than set 2 (33% vs 20%). Median age at diagnosis is
similar in both sets (51 and 52 years old respectively). There was
no significant difference in the morphology, histopathological
grade or clinical stage of the cases by set or by prevalent/incident
status.
Ovarian cancer study subjects
Ovarian cancer cases and controls from three different studies
were used: the SEARCH ovarian cancer study from the United
Kingdom, the MALOVA study from Denmark, and the FROC
study from the USA. We have described these studies in detail in
a previous report [22]. Briefly, the SEARCH ovarian cancer study
comprises 730 invasive epithelial ovarian cancer cases collected
from the East Anglian, West Midlands cancer registries in the UK.
The same series of 2280 subjects from the EPIC-Norfolk cohort
described for the breast cancer study (see above) were used as
controls for the ovarian cancer study, plus a further 855 randomly
selected female controls from the same cohort. The MALOVA
study comprises 456 invasive epithelial ovarian cancer cases
(median age 60 years) and 1231 controls (median age 57 years)
randomly drawn from the same study area. Controls were of
similar age range as cases, but not individually age matched. The
FROC study contains 327 invasive ovarian cases and 429 age-
matched controls – non-white subjects from FROC were excluded
from this analysis.
Tag SNP selection
The principal hypothesis underlying the experiment is that there
are one or more common SNPs in BRIP1 that are associated with
an altered risk of the ovarian/breast cancer. We therefore aimed
to identify a set of tagging SNPs [tSNPs] that efficiently tag all the
known common variants (MAF.0.05) and are likely to tag most
of the unknown common variants. We used data from the
International HapMap Project [Phase II #20] to select tSNPs.
The HapMap Project has genotyped a large number of SNPs in
several populations. We used data from the 30 parent-offspring
trios collected in 1980 from U.S. residents with North-Western
European ancestry by the Centre d’Etude du Polymorphisme
Humain [CEPH] for tSNP selection. The programme Tagger uses
a strategy that combines the simplicity of pairwise methods with
the potential efficiency of multimarker approaches [http://www.
broad.mit.edu/mpg/tagger/] [23]. The best measure of the extent
to which one SNP tags another SNP is the pairwise correlation
coefficient [rp
2], since the loss in power incurred by using a marker
SNP in place of a true causal SNP is directly related to this
measure. We aimed to define a set of tagging SNPs such that all
known common SNPs had an estimated rp
2.0.8 with at least one
tagging SNP. However, some SNPs are poorly correlated with
other single SNPs but may be efficiently tagged by a haplotype
defined by multiple SNPs, thus reducing the number of tagging
SNPs needed. As an alternative, therefore, we aimed for the
correlation between each SNP and a haplotype of tagging SNPs
[rs
2] to be at.0.8.
Genotyping
All samples were genotyped using the TaqmanTM 7900HT
Sequence Detection System according to manufacturer’s instruc-
tions. Each assay was carried out using 10ng DNA in a 5 ml
reaction using TaqMan universal PCR master mix (Applied
Biosystems), forward and reverse primers and FAM and VIC
labelled probes designed by Applied Biosystems (ABI Assay-by-
design). Primer and probe sequences and assay conditions used for
each polymorphism analysed are detailed in Table S1. All assays
were carried out in 384-well plates and included 12 duplicate
samples in each plate for quality control. Genotypes were
determined using Allelic Discrimination Sequence Detection
Software (Applied Biosystems, Warrington UK). DNA samples
that did not give a clear genotype at the first attempt were not
repeated. The criteria for a successful genotype is that the
concordance rate for the duplicates should be $98% and the
overall call rate.95% (by study) with .90% for any individual
384-well plate. Plates failing this should be excluded. Hence, there
are variations in the number of samples successfully genotyped for
each polymorphism.
Statistics
Deviations of genotype frequencies in controls from those expected
under Hardy-Weinberg equilibrium (HWE) were assessed by x2
tests (1 d.f). The primary tests of association were univariate
analyses between each tagging SNP and breast/ovarian cancer.
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Genotype frequencies were compared in cases and controls using
unconditional logistic regression. Genotype specific risks with the
common homozygote as the baseline comparator were estimated
as odds ratios (OR) with associated 95% confidence intervals (95%
CI) by unconditional logistic regression. We also tested for rare
allele dose effect (assuming a multiplicative model). For the ovarian
cancer data, all the analyses were stratified by study. We tested
for heterogeneity between study strata by comparing logistic
regression models with and without a genotype-stratum interaction
term using likelihood-ratio tests.
In addition to the univariate analyses we carried out specific
haplotype tests for those combinations of alleles that tagged
specific SNPs. We also carried out a general comparison of
common haplotype frequencies in each gene haplotype block
utilising the data from all the tSNPs in that block. Haplotype
blocks were defined such that the common haplotypes (.5%
frequency) accounted for at least 80% of the haplotype diversity.
We considered haplotypes with greater than 2% frequency in at
least one study to be "common". Rare haplotypes were pooled.
For both specific haplotype marker tests and the general
comparison of haplotype frequencies by haplotype block, haplo-
type frequencies and subject-specific expected haplotype indicators
were calculated separately for each study using the programme
TagSNPs [24]. This implements an expectation substitution
approach to account for haplotype uncertainty given unphased
genotype data. Subjects missing .50% genotype data in each
block were excluded from haplotype analysis. We used un-
conditional logistic regression to test the null hypothesis of no
association between specific multi-marker tagging haplotype and
cancer, by comparing a model with terms for subject specific-
haplotype indicator with the intercept only model. The global null
hypothesis of no association between haplotype frequency (by
haplotype block) and cancer was tested, by comparing a model
with multiplicative effects for each common haplotype (treating the
most common haplotype as the referent) to the intercept-only
model. Haplotype specific odds ratios were also estimated with
their associated confidence intervals [25].
RESULTS
Using Hapmap CEPH data (Phase II #20), we identified 92
common SNPs in 198kb region containing the BRIP1 gene
(including 9kb up stream and 9 kb down stream of the gene).
Sixteen SNPs were initially chosen as tagging SNPs (tSNPs), but
four assays failed design. Thus, 12 tSNPs were selected for
genotyping. The mean rp
2 was 0.93 with 87 out of 92 SNPs tagged
by a single marker with rp
2.0.8. Two SNPs were tagged with
multi-marker haplotypes with rs
2.0.8 and one SNP was tagged
with r2 = 0.78. The two SNPs for which the assays failed were
poorly correlated with any other SNPs and so alternative tSNPs
could not be selected. These two were tagged with rp
2 of 0.16 and
0.06, respectively.
The 12 tSNPs were genotyped in approximately 2,300 breast
cancer cases and a similar number of controls from the UK. For
11 tSNPs, genotype frequency distributions in controls were close
to those expected under Hardy Weinberg Equilibrium (HWE)
(table S2). Genotype calling for one tSNP (rs6504074) did not pass
the quality assessment criteria with genotyping call rate ,95%.
Thus, this tSNP was removed from further analyses. There was no
difference in genotype frequencies between incident and prevalent
cases, nor was time between diagnosis and entry into the study
associated with genotype (data not show). The observed genotype
frequencies in breast cancer subjects are presented in Table S2.
Table 1 shows the results of the test for the comparison of
genotype frequencies (P-heterogeneity) between cases and controls.
There were no significant differences in genotype frequencies
between cases and controls for any of the 11 tSNPs tested (P.0.1),
and no SNP was genotyped in the second set of samples. Genotype
specific risks were close to unity and the tests for trend were not
significant for any tSNPs.
One SNP (rs4986765) was tagged by a haplotype comprising
the three common alleles of the tSNPs rs2191249, rs11871785 and
rs16945628. The frequency of this haplotype was similar in cases
(0.33) and in controls (0.32) (P = 0.33). Another SNP (rs1243935)
was tagged by the haplotype comprising two rare alleles of tSNPs
rs2191249 and rs6504074, but as the assay for the second of these
SNPs failed the specific haplotype frequency in cases and controls
could not be compared.
Genotyping quality was satisfactory for all 12 tSNPs in the
ovarian cancer studies. Genotype frequency distributions in
controls were close to those expected under HWE for all tSNPs
(table S3) - rs2191248 deviated slightly from HWE in one of the
three studies (MALOVA, P= 0.04). However, the discrimination
of genotypes for this tSNP were good and no deviation from HWE
was seen in cases suggesting this is a chance occurrence. Therefore
we included the data for this tSNP in further analyses.
The comparison of genotype frequencies (P-heterogeneity)
between cases and controls in the combined data from all three
ovarian cancer studies are presented in Table 1. Table S3 presents
the observed genotype frequencies by study. We found no
significant differences in genotype frequencies for any of the 12
stSNPs genotyped. The genotypic specific risks in the combined
data and the test for trend for each tSNP are also presented in
Table 1. We found evidence for a weak protective effect for the
rare allele of rs2191249, which was associated with a reduced
disease risk in a dose-dependant manner (OR=0.90 [95%CI
0.82–1.0] P-trend= 0.045) compared with common homozygotes.
There was also evidence for a borderline significant effect for the
rare allele of rs4988344, which was associated with an increased
risk in a dose-dependant manner (OR=1.15 [95%CI 1.02–
1.30], P-trend= 0.02), compared with common homozygotes.
There was no heterogeneity between the studies for either of
these tSNPs (P= 0.71 and 0.41 respectively). In logistic re-
gression model including both these SNPs there was little
attenuation of the per-allele risks (data not shown). There was
no difference in the three allele multi-marker tagging haplotype
for rs4986765 (P= 0.16) or two allele multi-marker tag for
rs1243935 (P= 0.22).
There were two LD blocks with common haplotypes, which
accounted for 91% and 83% of all haplotypes respectively
(Figure 1). rs11871785, rs1557720, rs11652980, rs2191249,
rs16945628 and rs2191248 were situated in block 1 and the
remaining tSNPs (rs16945643, rs6504074, rs2378908, rs4988344,
rs9908659 and rs2048718) were situated in block 2. The haplotype
frequencies for BRIP1 between cases and controls were estimated
after stratification. Haplotype specific risks for individual haplo-
types were close to unity compared with the most common one in
each block (data not shown). No significant differences in
individual haplotype frequencies were seen between cases and
controls for breast and ovarian cancer studies, nor in the global
test for a haplotype effect (P value for block 1 was 0.68 and 0.43, P
value for block 2 was 0.99 and 0.25 respectively for breast and
ovarian cancer).
Ovarian cancer is histologically a very heterogeneous disease.
Different histological subtypes may show different genetic
association, e.g, the proportion of serous tumours is higher in
BRCA1 associated ovarian cancer. Statistical power to identify sub-
group effects in the combined series of ovarian cancer cases was
limited, so we restricted sub-group analysis to serous cases only
SNPs and Breast/Ovarian Cancer
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(n = 698 in total). The comparison of genotype frequencies (P-
heterogeneity) between cases and controls and the genotype
specific risks for serous cases in the combined dataset are presented
in Table 2. Only rs4988344 showed a marginally significant
difference in genotype frequencies between cases and controls (P-
het = 0.027). In general, genotype specific risks were similar
between serous only cases and all cases combined, although there
were slightly increased risks in serous cases for the rare alleles of
rs4988344 (P trend= 0.008) and rs2378908 (P-trend= 0.015)
(Table 2). For rs2191249, the rare allele protective effect identified
in all cases was slightly stronger when serous only cases were
considered (P–trend= 0.026).
DISCUSSION
The role of abnormal DNA helicase function in the deregulation
of DNA repair and genomic stability, and in human cancer
development, is well documented. The functional interaction
between the DNA helicase BRIP1 and the breast/ovarian cancer
susceptibility gene BRCA1 makes common variants in BRIP1 good
candidates for low to moderate penetrance susceptibility to both
breast and ovarian cancer.
In this study, we evaluated the association between SNPs that
efficiently tag the common variation in the BRIP1 gene and the
risks of breast and ovarian cancer using a case-control study
design. The tSNPs that we tested were not chosen because they
were of any known functional significance. tSNP selection was
based on the latest Hapmap data (Phase II release # 20) in CEPH
DNA samples, which are of North Western European ancestry.
The tSNPs selected using these data provide good power to
capture all common variation [25]. Therefore, we are confident
that the set of tSNPs we chose adequately tag the known and
unknown common variants within the gene.
Previous studies have looked at the association between
a handful of common functional BRIP1 polymorphisms and
breast cancer risk. The Ser919Pro variant was found to increase
breast cancer risk in families using a ‘kin-cohort’ study design [20].
However, subsequent studies failed to confirm this finding [16,21].
Ser919Pro (MAF=0.45) was tagged by rs1557720 (rp
2 = 0.97). We
found no evidence of association between this SNP and breast
cancer risk (P = 0.39). Our study has 97% power to detect an allele
with this frequency with a type I error rate of 0.0001, even if the
true relative risk was 1.3.
Another study has indicated that the rare variant Arg173Cys
(tSNP rs4988345) impairs protein translocation to the nucleus and
might modify breast cancer susceptibility [17,26]. Since the minor
allele for this variant is very rare (MAF=0.008) in CEPH samples,
we have very limited power to confirm or refute this association
using the case-control population in the current study.
We found no evidence of association with breast cancer risk for
any of the tSNPs analysed in our study. The staged design provides
at least 85% power at a Type I error rate of 1023 to detect an
allele that explains 0.75% of the excess familial risk of breast
cancer and has been tagged with r2 = 0.8 – e.g.a co-dominant
allele with a frequency of 0.1 that confers a relative risk of 1.27.
Table 1. Breast and ovarian cancer genotype specific risks for each tSNP by study
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
dbSNP Study # cases # controls HetOR*[95% CI] HomOR*[95% CI] P_het P_trend
rs11871785 Breast Cancer 2181 2267 0.97 [0.85–1.09] 1.11 [0.91–1.34] 0.39 0.61
Ovarian Cancer 1492 4750 1.07 [0.95–1.22] 1.05 [0.86–1.27] 0.55 0.41
rs1557720 Breast Cancer 2156 2247 0.97 [0.85–1.10] 0.93 [0.78–1.10] 0.69 0.39
Ovarian Cancer 1332 4229 1.05 [0.92–1.21] 1.08 [0.90–1.31] 0.65 0.36
rs11652980 Breast Cancer 2182 2275 0.97 [0.80–1.16] 0.69 [0.19–2.46] 0.80 0.62
Ovarian Cancer 1490 4765 0.95 [0.78–1.17] 1.21 [0.38–3.91] 0.85 0.73
rs2191249 Breast Cancer 2189 2277 0.97 [0.86–1.10] 1.14 [0.90–1.43] 0.42 0.64
Ovarian Cancer 1328 4242 0.93 [0.82–1.07] 0.75 [0.58–0.99] 0.09 0.045
rs16945628 Breast Cancer 2176 2271 0.97 [0.85–1.09] 1.09 [0.90–1.32] 0.48 0.70
Ovarian Cancer 1495 4754 0.92 [0.81–1.05] 0.89 [0.73–1.09] 0.33 0.15
rs2191248 Breast Cancer 2162 2264 1.05 [0.93–1.20] 1.02 [0.84–1.23] 0.71 0.62
Ovarian Cancer 1483 4741 1.02 [0.90–1.16] 1.12 [0.92–1.35] 0.51 0.32
rs16945643 Breast Cancer 2171 2265 1.02 [0.85–1.21] 1.05 [0.51–2.15] 0.98 0.82
Ovarian Cancer 1485 4746 1.01 [0.86–1.20] 1.20 [0.58–2.49] 0.89 0.75
rs6504074 Breast Cancer ND ND ND ND ND ND
Ovarian Cancer 1309 3968 0.94 [0.81–1.10] 0.85 [0.64–1.12] 0.26 0.25
rs2378908 Breast Cancer 2190 2277 1.04 [0.90–1.20] 0.74 [0.47–1.17] 0.36 0.86
Ovarian Cancer 1302 4254 1.15 [0.99–1.33] 1.11 [0.70–1.77] 0.20 0.09
rs4988344 Breast Cancer 2189 2278 0.98 [0.86–1.12] 1.02 [0.69–1.50] 0.97 0.89
Ovarian Cancer 1330 4265 1.11 [0.97–1.28] 1.49 [1.03–2.16] 0.05 0.02
rs9908659 Breast Cancer 2164 2266 0.97 [0.86–1.10] 1.04 [0.87–1.24] 0.74 0.85
Ovarian Cancer 1492 4749 0.99 [0.87–1.13] 1.06 [0.88–1.27] 0.78 0.64
rs2048718 Breast Cancer 2170 2264 0.92 [0.81–1.06] 0.99 [0.83–1.17] 0.46 0.76
Ovarian Cancer 1473 4741 0.93 [0.81–1.06] 1.01 [0.86–1.20] 0.39 0.98
1 odds ratio, 2 confidence interval, * compared with common homozygote. Confidence intervals that do not reach or cross 1.00 and P- values,0.05 are in bold type
doi:10.1371/journal.pone.0000268.t001..
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Therefore, it is unlikely that common variants in BRIP1 contribute
significantly to breast cancer risk. However, we cannot exclude the
possibility that the alleles we investigated are associated with
smaller risks. Power to detect alleles explaining 0.5% of the excess
familial risk is approximately 65%, and power to detect rarer
susceptibility variants that are weakly correlated with the
polymorphisms we examined is low. Furthermore some known
common variants were poorly tagged, because of tSNP assay
failure. Again power to detect association with these SNPs is
limited.
To our knowledge, this is the first study to evaluate the
association between common variants in BRIP1 and the risks of
epithelial ovarian cancer. We found some evidence of association
with disease risk for two of the 12 tSNPs tested- rs2191249 and
Figure 1. Linkage disequilibrium between the 92 common variants (MAF.0.05) in HapMap CEPH trios. Each square represents the correlation (r2)
between each pair of SNPs with darker shades representing stronger LD. Tag SNPs are indicated with those SNPs that failed assay design being
shown in grey font.
doi:10.1371/journal.pone.0000268.g001
Table 2. Serous type ovarian cancer genotype specific risks for each tSNP
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
dbSNP # serous cases # controls HetOR*[95% CI] HomOR*[95% CI] P-het P_trend
rs11871785 698 4750 1.01 [0.84–1.20] 1.09 [0.84–1.42] 0.80 0.59
rs1557720 698 4229 1.14 [0.94–1.39] 1.16 [0.89–1.51] 0.36 0.20
rs11652980 698 4765 0.97 [0.73–1.28] 1.54 [0.33–7.25] 0.85 0.95
rs2191249 698 4242 0.83 [0.69–1.00] 0.75 [0.51–1.09] 0.08 0.026
rs16945628 698 4754 0.78 [0.65–0.93] 1.00 [0.77–1.29] 0.01 0.21
rs2191248 698 4741 0.94 [0.79–1.12] 1.05 [0.80–1.36] 0.66 0.96
rs16945643 698 4746 1.03 [0.82–1.30] 1.72 [0.72–4.15] 0.50 0.46
rs6504074 698 3968 0.90 [0.74–1.09] 0.93 [0.67–1.30] 0.51 0.35
rs2378908 698 4254 1.21 [0.98–1.49] 1.73 [0.99–3.01] 0.05 0.015
rs4988344 698 4265 1.20 [0.98–1.46] 1.78 [1.10–2.89] 0.027 0.008
rs9908659 698 4749 0.87 [0.73–1.04] 0.91 [0.71–1.17] 0.33 0.27
rs2048718 698 4741 0.93 [0.77–1.13] 1.12 [0.89–1.41] 0.22 0.42
*compared with common homozygote. Confidence intervals that do not reach or cross 1.00 and P- values,0.05 are in bold type
doi:10.1371/journal.pone.0000268.t002..
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rs4988344. However, these associations were only of borderline
significance, and so need to be interpreted with some caution.
Despite the large sample size, neither association is highly
significant (P = 0.047 and 0.02 respectively) and the P-values have
not been adjusted for multiple hypothesis testing. As the tSNPs are
correlated, the test statistics are not independent, and standard
methods for adjusting for multiple testing, such as the Bonferroni
correction, are too conservative. Therefore we used a simulation
to determine an empirical P-value for the most significant result
(P-trend= 0.02 for rs4988344). In this analysis, we randomly
shuffled the case-control status among individuals multiple times,
and estimated how frequently a P-value,0.02 was obtained from
the randomly permutated data. This method also accounts for the
testing of multiple genetic models with each SNP. In 1,000
permutations a P,0.02 was observed on 357 occasions, giving the
most significant P-value corrected for multiple testing of 0.36.
Thus it is likely that the positive result is a chance finding.
Disease heterogeneity could also lead to false positive reporting
or mask the presence of true associations. When we stratified cases
according to histological sub-type we found that the strength of
association with ovarian cancer risks improved for rs4988344 and
rs2378908 when cases of serous histology only were considered (P
trend= 0.008 and 0.015 respectively). Once again, caution is
required when interpreting these data. There is an inevitable loss
of statistical power when stratifying cases into clinical sub-types,
and after adjusting for multiple testing, the most significant of
these associations (P-trend= 0.008 for rs4988344) was P= 0.17.
Another explanation for a spurious association could be hidden
population stratification. This occurs when allele frequencies differ
between population sub-groups and cases and controls are drawn
differentially from those sub-groups. The three ovarian cancer
case-control studies used in the present analysis were from the UK,
Denmark and USA. However, all analyses were restricted to
subjects of the same ethnic origin (white, Western European) and
so population stratification is unlikely to be explanation for
erroneous associations. Even if stratification were present, it is
unlikely that the same degree of stratification would occur in all
three studies.
In combination, the three ovarian cancer studies has more than
80% power to detect a common allele that explains 0.75% of the
excess familial risk at a type I error rate of 1023 (for example an
allele with frequency 0.2 that confers a relative risk of 1.3), and
more than 55% power to detect a common allele that explains
0.5% of the excess familial risk.
Assuming the genetic associations we identified are real, they
may either be due to a direct causative effect of the SNPs tested, or
because these tSNPs are in linkage disequilibrium and serve as
markers for the real determinant of a disease. rs2191249 and
rs4988344 are both intronic and neither is strongly correlated with
other known SNPs that are more likely to have functional role.
The bioinformatics tool PupaSNP (http://pupanp.bioinfo.cnio.es)
suggests neither variant has a functional effect or dramatically
alters the structure of BRIP1. Thus, it seems likely that any true
causal variant(s) will be in linkage disequilibrium with rs2191249
or rs4988344. All the known common coding SNPs, 39UTR SNPs
and 59UTR SNPs were tagged by our selected panel of tSNPs with
r2.0.95 and were not associated with disease. However, we
cannot exclude the possibility that unidentified variants exist in the
promoter or regulatory region or intron-exon boundaries, which
affect the transcription of BRIP1, and are tagged by the two tSNPs
for which we find association.
In conclusion, we have genotyped 12 tSNPs that tag the
common variants in BRIP1 in breast and ovarian cancer case
control series. We found no association with breast cancer risk for
any tSNP; but we found evidence of borderline significant
associations with invasive ovarian cancer risk for two tSNPs of
unknown related function to BRIP1. The observed associations
with ovarian cancer risk warrant further evulation in independent
case-control studies.
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